# EDGAR Filing Document

**Accession Number:** 0001550395
**File Stem:** 0001209191-23-007827
**Filing Date:** 2023-2
**Character Count:** 7018
**Document Hash:** 836c0dd16e214ea21dca3d51d4e7073b
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001209191-23-007827.hdr.sgml**: 20230208

**ACCESSION NUMBER**: 0001209191-23-007827

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20230206

**FILED AS OF DATE**: 20230208

**DATE AS OF CHANGE**: 20230208

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** ALTSHULER DAVID
- **CENTRAL INDEX KEY:** 0001550395

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-19319
- **FILM NUMBER:** 23599810

**MAIL ADDRESS:**
- **STREET 1:** C/O VERTEX PHARMACEUTICALS INCORPORATED
- **STREET 2:** 130 WAVERLY STREET
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02139
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** VERTEX PHARMACEUTICALS INC / MA
- **CENTRAL INDEX KEY:** 0000875320
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 043039129
- **STATE OF INCORPORATION:** MA
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 50 NORTHERN AVENUE
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02210
- **BUSINESS PHONE:** 6173416393

**MAIL ADDRESS:**
- **STREET 1:** 50 NORTHERN AVENUE
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02210

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>ALTSHULER DAVID<br><sub>(Last) (First) (Middle)</sub><br>C/O VERTEX PHARMACEUTICALS INCORPORATED<br>50 NORTHERN AVENUE<br><sub>(Street)</sub><br>BOSTON, MA 02210<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2023-02-06 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_EVP, Global Research and CSO_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>VERTEX PHARMACEUTICALS INC / MA [ VRTX ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2023-02-06 |  | M |  | 1304 | A | $187.53 | 69949 | D |  |
| Common Stock | 2023-02-06 |  | S<sup>(1)</sup> |  | 12 | D | $300.39 | 69937 | D |  |
| Common Stock | 2023-02-06 |  | S<sup>(1)</sup> |  | 70 | D | $302.00 | 69867 | D |  |
| Common Stock | 2023-02-06 |  | S<sup>(1)</sup> |  | 100 | D | 303.64<sup>(2)(3)</sup> | 69767 | D |  |
| Common Stock | 2023-02-06 |  | S<sup>(1)</sup> |  | 349 | D | 305.08<sup>(2)(4)</sup> | 69418 | D |  |
| Common Stock | 2023-02-06 |  | S<sup>(1)</sup> |  | 620 | D | 306.70<sup>(2)(5)</sup> | 68798 | D |  |
| Common Stock | 2023-02-06 |  | S<sup>(1)</sup> |  | 153 | D | 309.06<sup>(2)(6)</sup> | 68645 | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Stock Option (Right to Buy) | $187.53 | 2023-02-06 |  | M |  |  | 1304 | <sup>(7)</sup> | 2029-02-05 | Common Stock | 1304 | $0.00 | 0 | D |  |

---

### Footnotes:

(1) Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1.

(2) Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

(3) Open market sales reported on this line occurred at a weighted average price of $303.64 (range $303.37 to $304.27).

(4) Open market sales reported on this line occurred at a weighted average price of $305.08 (range $304.72 to $305.43).

(5) Open market sales reported on this line occurred at a weighted average price of $306.70 (range $306.32 to $307.25).

(6) Open market sales reported on this line occurred at a weighted average price of $309.06 (range $308.76 to $309.42).

(7) Fully vested.

**Signature:** /s/ Christiana Stevenson, Attorney-in-Fact  
**Date:** 2023-02-08

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**